#United States #Long Beach #MemorialCare #Stroke Research

MemorialCare Long Beach Medical Center Launches NIH-Funded Stroke Study

In a significant step towards advancing stroke treatment, MemorialCare Long Beach Medical Center has joined a nationwide initiative funded by the National Institutes of Health (NIH) to explore innovative therapies for intracerebral hemorrhage (ICH). This Phase 3 clinical trial, known as the FASTEST trial, seeks to evaluate the efficacy of recombinant Factor VIIa (rFVIIa) in mitigating brain bleeding, which is a critical and life-threatening condition associated with high mortality rates.

Understanding Intracerebral Hemorrhage

Intracerebral hemorrhage is a severe form of stroke that occurs when a blood vessel in the brain ruptures, leading to bleeding within the tissue. This can create immense pressure, resulting in damage to surrounding brain structures. Alarmingly, ICH accounts for a significant percentage of the estimated 17 million strokes that occur globally each year, making it one of the deadliest types, with a mortality rate exceeding 40%. Currently, no proven treatments exist to stop this type of brain bleeding, highlighting the urgent need for effective solutions.

Dr. Nima Ramezan, the medical director of the MemorialCare Neuroscience Institute, emphasizes the importance of timely intervention.